Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.
The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers.
C4 Therapeutics, Inc. has strategic collaborations with F.
Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 20, 24 | -0.41 Increased by +42.25% | -0.35 Decreased by -17.14% |
| Feb 22, 24 | -0.70 Increased by +9.09% | -0.68 Decreased by -2.94% |
| Nov 1, 23 | -0.52 Increased by +20.00% | -0.66 Increased by +21.21% |
| Aug 8, 23 | -0.73 Decreased by -30.36% | -0.69 Decreased by -5.80% |
| May 4, 23 | -0.71 Decreased by -9.23% | -0.75 Increased by +5.33% |
| Feb 23, 23 | -0.77 Decreased by -148.39% | -0.74 Decreased by -4.05% |
| Nov 3, 22 | -0.65 Decreased by -27.45% | -0.67 Increased by +2.99% |
| Aug 4, 22 | -0.56 Decreased by -9.80% | -0.69 Increased by +18.84% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 11.07 M Increased by +63.93% | -27.04 M Increased by +13.97% | Decreased by -244.19% Increased by +47.52% |
| Jun 30, 23 | 2.66 M Decreased by -80.74% | -35.92 M Decreased by -30.91% | Decreased by -1.35 K% Decreased by -579.81% |
| Mar 31, 23 | 3.76 M Decreased by -50.89% | -33.94 M Decreased by -6.49% | Decreased by -902.85% Decreased by -116.82% |
| Dec 31, 22 | 2.85 M Decreased by -85.79% | -36.08 M Decreased by -130.41% | Decreased by -1.26 K% Decreased by -1.52 K% |
| Sep 30, 22 | 6.75 M Decreased by -20.54% | -31.43 M Decreased by -27.33% | Decreased by -465.32% Decreased by -60.24% |
| Jun 30, 22 | 13.83 M Increased by +41.44% | -27.44 M Decreased by -21.52% | Decreased by -198.35% Increased by +14.08% |
| Mar 31, 22 | 7.65 M Increased by +3.07% | -31.87 M Decreased by -51.98% | Decreased by -416.40% Decreased by -47.45% |
| Dec 31, 21 | 20.08 M Increased by +143.02% | -15.66 M Increased by +28.16% | Decreased by -77.99% Increased by +70.44% |